ON123300 10 mg | 99.22%
TargetMol
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
More Information Supplier PageON123300
Search Results
ON123300 2 mg | 99.22%
TargetMol
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
More Information Supplier PageON123300
TAK-580 25 mg | 99.77%
TargetMol
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
More Information Supplier PageTAK-580
TAK-580 10 mg | 99.77%
TargetMol
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
More Information Supplier PageTAK-580
TAK-580 2 mg | 99.77%
TargetMol
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials.
More Information Supplier PageTAK-580
Galeterone 25 mg | 99.57%
TargetMol
Galeterone is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a […]
More Information Supplier PageGaleterone
Rhamnose monohydrate 200 mg | 99.80%
TargetMol
L(+)-Rhamnose (Rham) is a naturally-occurring deoxy sugar that is found primarily in plants and some bacteria.
More Information Supplier PageRhamnose monohydrate
Nicaraven 25 mg | 99.77%
TargetMol
Nicaraven, a hydroxyl radical scavenger, has neuroprotective and antivasospastic effects.
More Information Supplier PageNicaraven
Nicaraven 200 mg | 99.77%
TargetMol
Nicaraven, a hydroxyl radical scavenger, has neuroprotective and antivasospastic effects.
More Information Supplier PageNicaraven
Ospemifene 25 mg | 99.73%
TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information Supplier PageOspemifene
